Loading stock data…
Cibus (CBUS)
$1.43+0.07 (+5.15%)
Market ClosedLast close Jun 29
Cibus, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cibus, Inc. in the Healthcare sector is trading at $1.43 with a market capitalization of $104M. Wall Street consensus targets $14.67 (3 analysts), implying a +925.6% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 20.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +925.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.68M↑ | $1.06M↑ | $615,000↓ | $933,000↓ | $1.03M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.12M↑ | -$13.46M↑ | -$15.44M↑ | -$17.95M↑ | -$20.62M |
| Net Income | -$21.22M↑ | -$31.29M↓ | -$23.54M↑ | -$25.37M↑ | -$46.89M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$104.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-285.85%
Volume
Today's trading volume
251,479
Recent News
Cibus, Inc. Q1 2026 Earnings Call Summary
Moby summary of Cibus, Inc.'s Q1 2026 earnings call
Cibus Inc (CBUS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cibus Inc (CBUS) strengthens its market position with significant progress in commercialization and regulatory support, despite facing financial hurdles and product launch delays.
Cibus Q1 Earnings Call Highlights
Cibus (NASDAQ:CBUS) reported first-quarter 2026 results and said it is advancing toward commercialization across its rice and sustainable ingredients programs, while also reducing expenses and extending its cash runway into late in the first quarter of 2027. Peter Beetham, Cibus’ co-founder, interi
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
Cibus (CBUS) delivered earnings and revenue surprises of +5.71% and +29.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates
Bioceres Crop (BIOX) delivered earnings and revenue surprises of -220.00% and -29.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?